Kodiak Sciences. has filed a patent for antagonizing antibodies that target complement factor D (CFD) to treat age-related macular degeneration and other diseases. The invention includes methods for using these antibodies alone or in combination with other therapeutics. GlobalData’s report on Kodiak Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kodiak Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kodiak Sciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Kodiak Sciences's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding to complement factor d for treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Kodiak Sciences Inc

A recent patent application (Publication Number: US20230382983A1) discloses a conjugate comprising an isolated antagonistic antibody that binds to complement factor D (CFD). The antibody includes specific amino acid sequences and mutations, along with a polymer covalently attached to the antibody. The patent also describes various configurations of the antibody's heavy and light chain variable regions, as well as the polymer's composition and molecular weight range. Additionally, the conjugate is designed to block interactions between CFD and C3bB, with specific binding characteristics outlined in the claims.

Furthermore, the patent application includes details on the structure of the conjugate, pharmaceutical compositions containing the conjugate, and methods for treating or preventing diseases by administering the conjugate to patients in need. The isolated antagonist antibody in the conjugate is specified to inhibit the proteolytic activity of CFD and prevent its binding to the C3bB complex. The patent also highlights the binding specificity of the antibody to human CFD, excluding certain mutations, and defines the epitope on CFD that the antibody targets. Overall, the patent application provides a comprehensive overview of the conjugate's composition, functionality, and potential applications in therapeutic interventions for various diseases.

To know more about GlobalData’s detailed insights on Kodiak Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies